BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, May 23, 2025
Breaking News: 100 days of uncertainty
See today's BioWorld Science
Home
» Carrick receives US IND approval for CDK12/13 inhibitor CT-7439 for advanced solid tumors
To read the full story,
subscribe
or
sign in
.
Cancer
Carrick receives US IND approval for CDK12/13 inhibitor CT-7439 for advanced solid tumors
Sep. 8, 2023
Carrick Therapeutics Ltd. has received FDA clearance of its IND application for CT-7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor.
BioWorld Science
Regulatory
Cancer
FDA
IND
